Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3âs ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.

Employees

Sector

Biotechnology & Medical Research

Calendar

02-18 - Q2 2026 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
14/01/26	0.4500 $	-2.17%	211,106
14/01/26	0.4600 $	+2.22%	6,655,421
13/01/26	0.4500 $	+3.45%	3,837,000
12/01/26	0.4350 $	0.00%	4,547,227
09/01/26	0.4350 $	-2.25%	3,520,913

Delayed Quote Australian S.E., January 14, 2026 at 11:09 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.4600AUD

Average target price

1.304AUD

Spread / Average Target

+183.48%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed Australian S.E. Other stock markets 23:10:02 14/01/2026 GMT			5-day change	1st Jan Change
0.4500 ^AUD	-2.17%		+4.65%	+8.43%

12-30	Immutep Says Bank of New York Mellon Increases Stake	MT
12-22	Immutep's Latest Update of Phase 1 Study Shows Substantial Reduction in T Cell Activity	MT

Capitalization	678M 453M 389M 362M 337M 628M 40.87B 4.16B 1.64B 19.59B 1.7B 1.66B 71.66B	P/E ratio 2026 *	-10.1x	P/E ratio 2027 *	-7.85x
Enterprise value	625M 418M 358M 334M 310M 579M 37.7B 3.84B 1.51B 18.06B 1.57B 1.53B 66.09B	EV / Sales 2026 *	48.4x	EV / Sales 2027 *	136x
Free-Float	96.21%	Yield 2026 *	-	Yield 2027 *	-

12-30	Immutep Says Bank of New York Mellon Increases Stake	MT
12-22	Immutep's Latest Update of Phase 1 Study Shows Substantial Reduction in T Cell Activity	MT
12-22	Immutep Limited Announces Positive Update on IMP761, a First-In-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study	CI
12-22	Immutep Completes Two Dosing Levels in Single-Ascending Dose Portion of Phase 1 Autoimmune Disease Trial	MT
12-16	Immutep Limited Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues At Robust Pace	CI
12-16	Immutep Says Nearly 300 Patients Enrolled for Lung Cancer Trial	MT
12-08	Immutep Shares Rise After Unit's Deal With Indian Drugmaker's Subsidiary	MT
12-08	Immutep, Dr. Reddy's Sign Licensing Deal for Cancer Drug Candidate	MT
12-08	Immutep and Dr. Reddy's enters into strategic collaboration for commercialisation of an innovative oncology drug, eftilagimod alfa	RE
12-08	Immutep SAS and Dr. Reddy?s Laboratories SA Enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa	CI
12-08	Dr Reddy's unit enters strategic collaboration with Immutep SAS	RE
12-08	India's Dr Reddy's signs licensing pact to sell Immutep's cancer drug	RE
12-08	Immutep enters into strategic collaboration with Dr. Reddy's	RE

13/10/25	Immutep Receives FDA Confirmation on Optimal Dose for Lead Immunotherapy Candidate	MT
27/06/24	Baird Trims Immutep Price Target to $6 From $7, Maintains Outperform Rating	MT
17/05/24	Capital One Initiates Immutep at Overweight Rating With $10 Price Target	MT
30/04/24	Canaccord Starts Immutep at Buy, Price Target is AU$1.00	MT
03/08/23	Baird Initiates Immutep With Outperform Rating, $7 Price Target	MT

Immutep Limited Share Price

Equities

IMM

AU000000IMM6

Biotechnology & Medical Research

Valuation: Immutep Limited

Chart: Immutep Limited

Latest news: Immutep Limited

Analysts' recommendations: Immutep Limited

Press Releases: Immutep Limited

News in other languages: Immutep Limited

Quotes and Performance

Course Extremes

Managers and Directors: Immutep Limited

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

12-22	Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study	AQ
12-15	Immutep : Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace	PU
12-09	SurgePays (NASDAQ: SURG) Expands Growth Strategy - New Lead-Driver to Boost Fintech Revenue - More Stocks Inside	AQ
12-08	Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa	AQ
12-08	Immutep : and Dr. Reddy’s Enter Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa	PU

1 day	-2.17%
1 week	+4.65%
Current month	+8.43%
1 month	+21.62%
3 months	+55.17%
6 months	+83.67%
Current year	+8.43%

1 week	0.42	0.47
1 month	0.36	0.47
Current year	0.41	0.47
1 year	0.22	0.47
3 years	0.22	0.48
5 years	0.22	0.72
10 years	0.1	0.72

Manager	Title	Age	Since
Marc Voigt CEO	Chief Executive Officer	53	08/07/2014
David Fang DFI	Director of Finance/CFO	-	28/02/2018
Frédéric Triebel CTO	Chief Tech/Sci/R&D Officer	71	11/12/2014

Director	Title	Age	Since
Russell Howard CHM	Chairman	76	16/11/2017
Marc Voigt BRD	Director/Board Member	53	08/07/2014
Frédéric Triebel BRD	Director/Board Member	71	12/09/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
IMMUTEP LIMITED	-2.17%	+4.65%	+40.62%	+50.00%	443M
LONZA GROUP AG	-0.46%	+3.79%	+2.50%	+13.83%	49.13B
IQVIA HOLDINGS INC.	-0.09%	+0.34%	+17.94%	+8.65%	41.14B
BEONE MEDICINES AG	-1.23%	+8.24%	+87.83%	+28.11%	38.85B
CELLTRION, INC.	-4.30%	-0.70%	+19.67%	+36.66%	32.74B
REVOLUTION MEDICINES, INC.	+1.06%	+51.81%	+184.75%	+302.86%	23.19B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	+8.08%	+6.48%	+26,107.15%	+4,371.14%	16.09B
MEDPACE HOLDINGS, INC.	+1.32%	+1.24%	+75.12%	+169.71%	17.14B
EUROFINS SCIENTIFIC SE	-1.53%	+4.65%	+46.91%	+11.70%	15.04B
ICON PUBLIC LIMITED COMPANY	+0.81%	-8.29%	-15.24%	-17.69%	14B
Average	+0.15%	+6.54%	+2,656.73%	+497.50%	24.78B
Weighted average by Cap.	-0.20%	+6.81%	+1,739.97%	+337.21%

	2026 *	2027 *
Net sales	12.91M 8.62M 7.4M 6.89M 6.41M 11.96M 778M 79.28M 31.19M 373M 32.36M 31.68M 1.36B	4.24M 2.83M 2.43M 2.26M 2.1M 3.92M 255M 26.01M 10.23M 122M 10.61M 10.39M 448M
Net income	-66.57M -44.46M -38.17M -35.54M -33.05M -61.69M -4.01B -409M -161M -1.92B -167M -163M -7.04B	-102M -68.34M -58.67M -54.64M -50.8M -94.84M -6.17B -628M -247M -2.96B -256M -251M -10.82B
Net Debt	-52.67M -35.17M -30.2M -28.12M -26.15M -48.81M -3.18B -323M -127M -1.52B -132M -129M -5.57B	-102M -67.81M -58.21M -54.21M -50.4M -94.1M -6.12B -623M -245M -2.93B -254M -249M -10.73B